| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
Total
2
Tetranor-pgem
Tetranor-pgem is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 73 references associated with Tetranor-pgem in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for Tetranor-pgem
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Tetranor-pgem
NCBI Entrez Crosslinks
All references with Tetranor-pgem
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Arai Y et al. | Prostaglandin E-Major Urinary Metabolite as a Biomarker for Inflammation in Ulcerative Colitis: Prostaglandins Revisited. | 2016 | Digestion | pmid:26788915 |
| Kakutani S et al. | Supplementation of arachidonic acid-enriched oil increases arachidonic acid contents in plasma phospholipids, but does not increase their metabolites and clinical parameters in Japanese healthy elderly individuals: a randomized controlled study. | 2011 | Lipids Health Dis | pmid:22188761 |
| Sanak M et al. | Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. | 2010 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:20627827 |
| Mutter R et al. | A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. | 2009 | Clin. Cancer Res. | pmid:19276291 |
| Dong LM et al. | Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. | 2009 | Cancer Epidemiol. Biomarkers Prev. | pmid:19861525 |
| Kozak KR et al. | Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2. | 2006 | Nat Clin Pract Rheumatol | pmid:16932737 |
| Csiki I et al. | Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. | 2005 | Clin. Cancer Res. | pmid:16166442 |
| Murphey LJ et al. | Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. | 2004 | Anal. Biochem. | pmid:15494133 |
| Fujiwara M et al. | Significant increase in prostaglandin E-main urinary metabolite by laxative administration: comparison with ulcerative colitis. | 2000 | Digestion | pmid:10773726 |
| Nishikawa A et al. | Enhancement of cell proliferation and prostaglandin biosynthesis by 1,8-dihydroxyanthraquinone in the rat large intestine. | 1997 | Carcinogenesis | pmid:9214611 |